RRML - The use of biomarkers in detecting subclinical cardiotoxicity in doxorubicin-based treatment for paediatric patients with acute lymphoblastic leukaemia
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2016): 55%

Română English


SCImago Journal & Country Rank


Advanced search


Top 10 downloaded articles
- January 2018 -
 
Retraction of article: Risk facto... 10
Romanian Review of Laboratory Med... 8
Myelodysplastic syndrome with mye... 6
Eulogy for Aurel BIZO... 6
Involvement of inflammatory marke... 5
The frequency of shiga-like toxin... 5
Effect of long period treatment w... 5
Eulogy for Professor Dr. Mircea C... 5
Biochemical and functional modifi... 4
Innate Immune Mechanisms in Myoca... 4

Log in

Concept, Design & Programming
Dr. Adrian Man

   
 
Nr. 25(2)/2017 DOI:10.1515/rrlm-2017-0014
XML
TXT

Research article

The use of biomarkers in detecting subclinical cardiotoxicity in doxorubicin-based treatment for paediatric patients with acute lymphoblastic leukaemia

Letiția Elena Radu, Andra Beldiman, Ioana Ghiorghiu, Alina Oprescu, Constantin Arion, Anca Coliță

Correspondence should be addressed to: Letiția Elena Radu

Abstract

The international standard protocol for acute lymphoblastic leukaemia (ALL), the most common haemato-oncological pathology at paediatric age, uses anthracyclines as antitumor agents, potentially associated with early or late onset cardiac damage. Currently, echocardiography is the gold standard in the diagnosis of cardiotoxicity, but several biomarkers are evaluated as a possible replacement, pending more extensive clinical studies. We started a prospective study in order to determine the role of two biomarkers, troponin and heart-type fatty acid binding protein, in the evaluation of cardiotoxicity in children over one year of age, diagnosed with ALL. Between February 2015 and April 2016, 20 patients were enrolled and monitored at diagnosis, during chemotherapy and four months after the end of reinduction, through cardiac evaluation and dosing of those two markers in five different points of the treatment protocol. During the first year of follow-up, the patients did not develop clinical signs of cardiac damage, but the study showed a slight increase in troponin levels during chemotherapy, with the return to baseline value after treatment cessation, and also a correlation with the total dose of anthracyclines given to the patient. On the other hand, the second biomarker, heart-type fatty acid binding protein, did not seem to be useful in detecting subclinical cardiac damage in these patients.

Keywords: acute lymphoblastic leukaemia;paediatric patients;cardiotoxicity;biomarkers

Received: 29.1.2016
Accepted: 1.4.2017
Published: 14.4.2017

 
  PDF Download full text PDF
(286 KB)
     
 
How to cite
Radu LE, Beldiman A, Ghiorghiu I, Oprescu A, Arion C, Coliță A. The use of biomarkers in detecting subclinical cardiotoxicity in doxorubicin-based treatment for paediatric patients with acute lymphoblastic leukaemia. Rev Romana Med Lab. 2017;25(2):157-64. DOI:10.1515/rrlm-2017-0014